# **Heart Failure Pharmacotherapy**

Based on the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

References:
[1] Classes of Heart Failure. American Heart Association. May 31, 2017. https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
[2] Heidenreich PA, Bozkurt R, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart
[2] Heidenreich PA, Bozkurt A, additional Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033]. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.00000000001063




Stage A

Stage B

Stage C

Stage D



Stage A	Stage B	Stage C (HFpEF)	Stage C (HFmrEF)	Stage C (HFimpEF)
<ul> <li>Control BP in patients with hypertension</li> <li>SGLT2i in patients with T2DM plus: <ul> <li>Established CVD or,</li> <li>High CV risk</li> </ul> </li> <li>Manage existing comorbidities</li> </ul>	<ul> <li>ACEi and evidence-based BB in patients with LVEF ≤ 40%</li> <li>If LVEF ≤ 40% and recent MI, use ARB if ACEi is not tolerated</li> </ul>	<ul> <li>Diuretics as needed (loop preferred)</li> <li>SGLT2i may be beneficial</li> <li>May consider MRA, ARB/ARNi if LVEF is closer to 50%</li> </ul>	<ul> <li>PRN diuretics (loop preferred)</li> <li>SGLT2i may be beneficial</li> <li>May consider MRA, ACEi/ARB/ ARNi, and evidence-based BB particularly if LVEF is closer to HFrEF threshold</li> </ul>	• Continue GDMT • Even if asymptomatic

## Stage C (HFrEF)

### **Specific patients**

- Hydralazine + isosorbide dinitrate African American patients on optimal therapy
- NYHA class III-IV
- Ivabradine
- NYHA class II-IV and LVEF ≤ 35% On GDMT including max tolerated BB NSR with resting HR ≥ 70 BPM
- Vericiguat
- NYHA class II-IV and LVEF < 45%</li> Recent HF worsening
- • Digoxin
- If symptomatic despite GDMT or Unable to tolerate GDMT
- Potassium binders e.g., Patiromer, sodium zirconium cyclosilicate • Patients with hyperkalemia (K+  $\geq$  5.5 mEq/L)
- while on RAASi
- Omega-3 PUFA (may consider as an adjunct) NYHA class II-IV

#### • $\uparrow$ H2O retention, $\uparrow$ vascular resistance, $\checkmark$ response to diuretics • Immediate onset, major induction/precipitation of HF COX inhibitors (e.g., NSAIDs) Potential blockage of calcium channel Potential blockage or calcium channel Intermediate onset, major induction/precipitation of HF Thiazolidinediones Saxagliptin, Alogliptin Mechanism is unclear • Immediate or delayed onset, major induction/precipitation of HF Flecainide, Disopyramide Proarrhythmic, negative inotropic effects Immediate to intermediate onset, major induction/precipitation of HF Proarrhythmic effects, beta blockade Sotalol mediate to intermediate onset, major induction/precipitation of HF Negative inotropic effects Dronedarone Immediate to intermediate onset, major induction/precipitation of HF Beta-1 stimulation. renin and aldosterone Doxazosin • Intermediate to delayed onset, moderate induction/precipitation of HF Diltiazem Negative inotropic effects · Immediate to intermediate onset, major induction/precipitation of HF Verapamil Negative inotropic effects Nifedipine mediate to intermediate onset, moderate induction/precipitation • Im of HF Recreated from Table 13 from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

ACEI: angiotensin-converting enzyme inhibitors ARB: angiotensin (II) receptor blocker ARNi: angiotensin receptor-neprilysin inhibitors BB: beta-blocker BNP: B-type natriuretic peptide

All patients

• ARNI or ACEI or ARB

• NYHA class II-IV

SGLT2i

• ARNI: NYHA class II-III

• ACEi or ARB: NYHA class II-IV

· Beta Blocker (evidence-based)

o eGFR > 30 mL/min/1.73m2

• With or without T2DM

Loop diuretics preferred

· Diuretics (as needed)

• Serum potassium < 5 mEq/L

Order of preference: ARNi > ACEi > ARB

· 36-hour washout required when switching

between ACEi and ARNi (and vice versa)

Bisoprolol, carvedilol, metoprolol succinate

• MRA (e.g. eplerenone, spironolactone)

BP: blood pressure CVD: cardiovascular disease eGFR: estimated glomerular filtration rate GDMT: guideline-directed medical therapy HF: heart failure

HFimpEF: heart failure with improved ejection fraction HFmrEF: heart failure with mildly reduced ejection frac HFpEF: heart failure with preserved ejection fraction HFrEF: heart failure with reduced ejection fraction UP left weat failure LV: left ventricula

Abbreviations

LVEF: left ventricular ejection fraction MI: myocardial infarction MRA: mineralocorticoid receptor antagonist NT-proBNP: N-terminal prohormone of B-type natriuretic peptide NYHA: New York Heart Association

PRN: as needed PUFA: polyunsaturated fatty acid RAASi: renin-angiotensin-aldosterone system inhibitor SGLT2I: sodium-glucose cotransporter-2 inhibitor T2DM: type 2 diabetes mellitus

## **Selected Medications That May Cause or Exacerbate HF**